International Journal of Hematology and Oncology
2024, Vol 34, Num 4 (Special Issue) Page(s): 001-012
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Chronic Myeloid Leukemia: Practical Issues in Diagnosis, Treatment and Follow-Up
Yahya BUYUKASIK1, Ibrahim C. HAZNEDAROGLU1, Osman ILHAN1
On behalf of Turkish CML Study Group, Ankara, TURKEY
Keywords: Chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL, Imatinib, Dasatinib, Nilotinib
Chronic myeloid leukemia (CML) is sometimes mentioned as the disease of “firsts”. 1) It is the first disease where the term “leukemia” was used. 2) It is the first neoplastic disorder which was found to be associated with a recurrent chromosomal abnormality. 3) It is the first disease where targeted therapy against a fusion protein was used. Entrance of BCR-ABL tyrosine kinase inhibitors, first imatinib and then dasatinib and nilotinib, into clinical practice within the last decade has fundamentally changed both treatment and follow-up of CML. In this review, practical points about CML have been summarized, with a special emphasis to treatment and follow-up.
Yahya BUYUKASIK1, Ibrahim C. HAZNEDAROGLU1, Osman ILHAN1
On behalf of Turkish CML Study Group, Ankara, TURKEY
Keywords: Chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL, Imatinib, Dasatinib, Nilotinib
Chronic myeloid leukemia (CML) is sometimes mentioned as the disease of “firsts”. 1) It is the first disease where the term “leukemia” was used. 2) It is the first neoplastic disorder which was found to be associated with a recurrent chromosomal abnormality. 3) It is the first disease where targeted therapy against a fusion protein was used. Entrance of BCR-ABL tyrosine kinase inhibitors, first imatinib and then dasatinib and nilotinib, into clinical practice within the last decade has fundamentally changed both treatment and follow-up of CML. In this review, practical points about CML have been summarized, with a special emphasis to treatment and follow-up.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |